4D Biomaterials secures £1.6m funding
4D Biomaterials, which has developed a new biomaterial used for 3D printing medical implants, has completed a £1.6m funding round.
The investment was led by DSW Ventures and backed by the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund, Mercia’s own funds, and existing investor SFC Capital.
The funding will be used to develop a range of products through partnerships with medical device companies and expand its team with the creation of five new jobs at its premises in MediCity.
Dr James Lapworth, Warwick Innovations, who has worked closely with the founding team since 2017 to support their ICURe customer discovery process, said: “This oversubscribed investment round into 4D Biomaterials recognises the progress that the team has made since spinning out, as well as the market opportunities which the company’s unique range of biodegradable 3D printing materials could address.”